In previous studies increased circulating levels of CD163 in patients with HCC and in diabetic patients with advanced NASH fibrosis, suggests CD163 as a biomarker for disease severity in NAFLD [74,56]. This evidence concerns the gene CD163 and metabolic dysfunction-associated steatotic liver disease.